- Author: Kirk M Chan-Tack, MD; Chief Editor: Pranatharthi Haran Chandrasekar, MBBS, MD more...
Botulism is an acute neurologic disorder that causes potentially life-threatening neuroparalysis due to a neurotoxin produced by Clostridium botulinum. The 3 main clinical presentations of botulism are as follows:
Essential update: FDA approves first heptavalent botulism antitoxin
On March 22, 2013, the FDA approved the first botulism antitoxin that can neutralize all 7 known botulinum nerve toxin serotypes. The heptavalent antitoxin is derived from horse plasma and is the only drug available for treating botulism patients over 1 year of age, including adults. It is also the only available drug for treating infant botulism that is not caused by nerve toxin type A or B.[1, 2, 3, 4]
Signs and symptoms
More than 90% of patients with botulism have 3-5 of the following signs or symptoms:
Extremely dry mouth unrelieved by drinking fluids
Generally, botulism progresses as follows:
Preceding or following the onset of paralysis are nonspecific findings such as nausea, vomiting, abdominal pain, malaise, dizziness, dry mouth, dry throat, and, occasionally, sore throat
Cranial nerve paralysis manifests as blurred vision, diplopia, ptosis, extraocular muscle weakness or paresis, fixed/dilated pupils, dysarthria, dysphagia, and/or suppressed gag reflex
Additional neurologic manifestations include symmetrical descending paralysis or weakness of motor and autonomic nerves
Respiratory muscle weakness may be subtle or progressive, advancing rapidly to respiratory failure
The autonomic nervous system is also involved in botulism, with manifestations that include the following:
Paralytic ileus advancing to severe constipation
Bladder distention advancing to urinary retention
Other neurologic findings include the following:
Changes in deep tendon reflexes, which may be either intact or diminished
Incoordination due to muscle weakness
Absence of pathologic reflexes and normal findings on sensory and gait examinations
Normal results on mental status examination
See Clinical Presentation for more detail.
A mouse neutralization bioassay confirms botulism by isolating the botulinum toxin. Toxin may be identified in the following:
C botulinum may be grown on selective media from samples of stool or foods. Note that the specimens for toxin analysis should be refrigerated, but culture samples of C botulinum should not be refrigerated. Wound cultures that grow C botulinum suggest the presence of wound botulism.
Characteristic electromyographic findings in patients with botulism include the following:
Brief, low-voltage compound motor-units
Small M-wave amplitudes
Overly abundant action potentials
An incremental increase in M-wave amplitude with rapid repetitive nerve stimulation may help to localize the disorder to the neuromuscular junction.
See Workup for more detail.
Rigorous and supportive care, including use of the following, is essential in patients with botulism:
Meticulous airway management - Of paramount importance, since respiratory failure is the most important threat to survival in patients with botulism
Cathartics and enemas - Administered to patients with bowel sounds to remove unabsorbed botulinum toxin from the intestine
Stress ulcer prophylaxis - A standard component of intensive care management
Nasogastric suction and intravenous hyperalimentation - Helpful if an ileus is present; if no ileus is present, tube feeding can be used for nutritional supplementation
Foley catheter - Often used to treat bladder incontinence; the catheter must be monitored conscientiously and changed regularly
Antibiotic therapy - Useful in wound botulism, but has no role in foodborne botulism
Magnesium salts, citrate, and sulfate should not be administered, because magnesium can potentiate the toxin-induced neuromuscular blockade.
Wound botulism requires the following:
Incision and thorough debridement of the infected wound
High-dose intravenous penicillin therapy
Prevention of nosocomial infections
Measures to reduce the risk of nosocomial infections include the following:
Close observation for hospital-acquired infections - Especially pneumonia (particularly aspiration pneumonia); precaution against aspiration is also necessary
Close observation for urinary tract infection
Meticulous skin care - To prevent decubital ulcers and skin breakdown
Careful attention to peripheral and central intravenous catheters with regular site rotation to reduce the risks of thrombophlebitis, cellulitis, and line infections should be part of the patient’s supportive care.
Botulism is an acute neurologic disorder that causes potentially life-threatening neuroparalysis due to a neurotoxin produced by Clostridium botulinum. The toxin binds irreversibly to the presynaptic membranes of peripheral neuromuscular and autonomic nerve junctions. Toxin binding blocks acetylcholine release, resulting in weakness, flaccid paralysis, and, often, respiratory arrest. Cure occurs following sprouting of new nerve terminals.
The 3 main clinical presentations of botulism include infant botulism (IB), foodborne botulism (FBB), and wound botulism (WB). Additionally, because of the potency of the toxin, the possibility of botulism as a bioterrorism agent or biological weapon is a great concern. For more information, see CBRNE – Botulism.
Infant botulism is caused by ingested C botulinum spores that germinate in the intestine and produce toxin. These spores typically come from bee honey or the environment. Most infants fully recover with supportive treatment; the attributed infant mortality rate is less than 1%. Improperly canned or home-prepared foods are common sources of the toxin that can result in foodborne botulism. Wound botulism results from contamination of a wound with toxin-producing C botulinum. Foodborne botulism and wound botulism occur predominantly in adults and are the focus of this article.
C botulinum is an anaerobic gram-positive rod that survives in soil and marine sediment by forming spores. Under anaerobic conditions that permit germination, it synthesizes and releases a potent exotoxin. Microbiologically, the organism stains gram-positive in cultures less than 18 hours old. The organism may stain gram-negative after 18 hours of incubation, potentially complicating attempts at diagnosis. On a molecular weight basis, botulinum toxins are the most potent toxins known.
Eight antigenically distinct C botulinum toxins are known, including A, B, C (alpha), C (beta), D, E, F, and G. Each strain of C botulinum can produce only a single toxin type. Types A, B, E, and, rarely, F cause human disease. Toxins A and B are the most potent, and the consumption of small amounts of food contaminated with these types has resulted in full-blown disease. During the last 20 years, toxin A has been the most common cause of foodborne outbreaks; toxins B and E follow in frequency. In 15% of C botulinum infection outbreaks, the toxin type is not determined. Toxins C and D cause disease in various animals. Type G toxin has been associated with sudden death but not with neuroparalytic illness. It was isolated from autopsy material from 5 patients in Switzerland in 1977.
The mechanism of action involves toxin-mediated blockade of neuromuscular transmission in cholinergic nerve fibers. This is accomplished by either inhibiting acetylcholine release at the presynaptic clefts of the myoneural junctions or by binding acetylcholine itself. Toxins are absorbed from the stomach and small intestine, where they are not denatured by digestive enzymes. Subsequently, they are hematogenously disseminated and block neuromuscular transmission in cholinergic nerve fibers. The nervous, gastrointestinal, endocrine, and metabolic systems are predominantly affected.
Because the motor end plate responds to acetylcholine, botulinum toxin ingestion results in hypotonia that manifests as descending symmetric flaccid paralysis and is usually associated with gastrointestinal symptoms of nausea, vomiting, and diarrhea. Cranial nerves are affected early in the disease course. Later complications include paralytic ileus, severe constipation, and urinary retention.
Wound botulism results when wounds are contaminated with C botulinum spores. Wound botulism has developed following traumatic injury that involved soil contamination, among injection drug users (particularly those who use black-tar heroin ), and after cesarean delivery. The wound may appear deceptively benign. Traumatized and devitalized tissue provides an anaerobic medium for the spores to germinate into vegetative organisms and to produce neurotoxin, which then disseminates hematogenously. The nervous, endocrine, and metabolic systems are predominantly affected. Symptoms develop after an incubation period of 4-14 days, with a mean of 10 days. The clinical symptoms of wound botulism are similar to those of foodborne botulism except that gastrointestinal symptoms (including nausea, vomiting, diarrhea) are uncommon.
In the United States, approximately 154 cases of botulism are reported annually to the Centers for Disease Control and Prevention (CDC). Infant botulism accounts for nearly 75% of all botulism cases.
The incidence of foodborne botulism is approximately 24 cases per year. The incidence of wound botulism is 3 cases per year. The incidence of infant botulism is 71 cases per year, with a mean age of 3 months.
Toxin A is found predominantly west of the Mississippi River. Toxin B is found most commonly in the eastern United States. Toxin E is found in northern latitudes, such as the Pacific Northwest, the Great Lakes region, and Alaska. The frequency of botulism in native Alaskans is among the highest in the world. Toxin E outbreaks are frequently associated with fish products.
Human botulism is found worldwide. Spores from C botulinum strains that produce type A or B toxins are distributed widely in the soil and have been found throughout the world. Toxin type B is commonly found in Europe. Toxin G was originally isolated in Switzerland.
Mortality rates vary based on the age of the patient and the type of botulism. Foodborne botulism carries an overall mortality rate of 5-10%. Wound botulism carries a mortality rate that ranges from 15-17%. The risk of death due to infant botulism is usually less than 1%.
The recovery period from botulism is often prolonged (30-100 d). Some patients demonstrate residual weakness or autonomic dysfunction for 1 year after the onset of the illness. However, most patients achieve full neurologic recovery. Permanent deficits may occur in those who sustain significant hypoxic insults.
Wound botulism is more common in males. Foodborne botulism has no sexual predilection.
Foodborne botulism and wound botulism predominately occur in adults. The mean age of infant botulism is 3 months.
Lowes R. FDA Approves First Heptavalent Botulism Antitoxin. Medscape Medical News. Mar 25 2013. Available at http://www.medscape.com/viewarticle/781389. Accessed: April 3 2013.
US Food and Drug Administration. FDA Approves First Botulism Antitoxin for Use in Neutralizing All Seven Known Botulinum Nerve Toxin Serotypes. FDA. Mar 22 2013. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345128.htm. Accessed: April 3 2013.
Hill SE, Iqbal R, Cadiz CL, Le J. Foodborne botulism treated with heptavalent botulism antitoxin. Ann Pharmacother. 2013 Feb. 47(2):e12. [Medline].
Webb RP, Smith LA. What next for botulism vaccine development?. Expert Rev Vaccines. 2013 May. 12(5):481-92. [Medline].
[Guideline] Bossi P, Tegnell A, Baka A, et al. Bichat guidelines for the clinical management of botulism and bioterrorism-related botulism. Euro Surveill. 2004 Dec 15. 9(12):E13-4. [Medline].
Passaro DJ, Werner SB, McGee J, et al. Wound botulism associated with black tar heroin among injecting drug users. JAMA. 1998 Mar 18. 279(11):859-63. [Medline].
Shaffer N, Wainwright RB, Middaugh JP, et al. Botulism among Alaska Natives. The role of changing food preparation and consumption practices. West J Med. 1990 Oct. 153(4):390-3. [Medline].
Yuan J, Inami G, Mohle-Boetani J, Vugia DJ. Recurrent wound botulism among injection drug users in California. Clin Infect Dis. 2011 Apr 1. 52(7):862-6. [Medline].
Angulo FJ, Getz J, Taylor JP, et al. A large outbreak of botulism: the hazardous baked potato. J Infect Dis. 1998 Jul. 178(1):172-7. [Medline].
St Louis ME, Peck SH, Bowering D, et al. Botulism from chopped garlic: delayed recognition of a major outbreak. Ann Intern Med. 1988 Mar. 108(3):363-8. [Medline].
Arnon SS. Creation and development of the public service orphan drug Human Botulism Immune Globulin. Pediatrics. 2007 Apr. 119(4):785-9. [Medline].
Cai S, Singh BR, Sharma S. Botulism diagnostics: from clinical symptoms to in vitro assays. Crit Rev Microbiol. 2007 Apr-Jun. 33(2):109-25. [Medline].
Cardoso F, Jankovic J. Clinical use of botulinum neurotoxins. Curr Top Microbiol Immunol. 1995. 195:123-41. [Medline].
Cherington M. Botulism: update and review. Semin Neurol. 2004 Jun. 24(2):155-63. [Medline].
Clemmens MR, Bell L. Infant botulism presenting with poor feeding and lethargy: a review of 4 cases. Pediatr Emerg Care. 2007 Jul. 23(7):492-4. [Medline].
Critchley EM, Mitchell JD. Human botulism. Br J Hosp Med. 1990 Apr. 43(4):290-2. [Medline].
Fox CK, Keet CA, Strober JB. Recent advances in infant botulism. Pediatr Neurol. 2005 Mar. 32(3):149-54. [Medline].
Glik D, Harrison K, Davoudi M, et al. Public perceptions and risk communications for botulism. Biosecur Bioterror. 2004. 2(3):216-23. [Medline].
Hallett M. One man's poison--clinical applications of botulinum toxin. N Engl J Med. 1999 Jul 8. 341(2):118-20. [Medline].
Hatheway CL. Botulism: the present status of the disease. Curr Top Microbiol Immunol. 1995. 195:55-75. [Medline].
Jahn R, Niemann H. Molecular mechanisms of clostridial neurotoxins. Ann N Y Acad Sci. 1994 Sep 15. 733:245-55. [Medline].
Lawrence DT, Dobmeier SG, Bechtel LK, et al. Food poisoning. Emerg Med Clin North Am. 2007 May. 25(2):357-73; abstract ix. [Medline].
Lecour H, Ramos H, Almeida B, et al. Food-borne botulism. A review of 13 outbreaks. Arch Intern Med. 1988 Mar. 148(3):578-80. [Medline].
Long SS. Infant botulism and treatment with BIG-IV (BabyBIG). Pediatr Infect Dis J. 2007 Mar. 26(3):261-2. [Medline].
Oguma K, Fujinaga Y, Inoue K. Structure and function of Clostridium botulinum toxins. Microbiol Immunol. 1995. 39(3):161-8. [Medline].
Roblot P, Roblot F, Fauchere JL, et al. Retrospective study of 108 cases of botulism in Poitiers, France. J Med Microbiol. 1994 Jun. 40(6):379-84. [Medline].
Schiavo G, Rossetto O, Tonello F, et al. Intracellular targets and metalloprotease activity of tetanus and botulism neurotoxins. Curr Top Microbiol Immunol. 1995. 195:257-74. [Medline].
Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med. 1998 Aug 1. 129(3):221-8. [Medline].
Slater PE, Addiss DG, Cohen A, et al. Foodborne botulism: an international outbreak. Int J Epidemiol. 1989 Sep. 18(3):693-6. [Medline].
Sobel J, Tucker N, Sulka A, et al. Foodborne botulism in the United States, 1990-2000. Emerg Infect Dis. 2004 Sep. 10(9):1606-11. [Medline].
Varma JK, Katsitadze G, Moiscrafishvili M, et al. Signs and symptoms predictive of death in patients with foodborne botulism--Republic of Georgia, 1980-2002. Clin Infect Dis. 2004 Aug 1. 39(3):357-62. [Medline].
Weber JT, Goodpasture HC, Alexander H, et al. Wound botulism in a patient with a tooth abscess: case report and review. Clin Infect Dis. 1993 May. 16(5):635-9. [Medline].
Wilcox PG, Morrison NJ, Pardy RL. Recovery of the ventilatory and upper airway muscles and exercise performance after type A botulism. Chest. 1990 Sep. 98(3):620-6. [Medline].